# Diabetes Management Update - Insulins

Dana Staat, PharmD  
Clinical Pharmacy Specialist - Internal Medicine  
Spectrum Health, Grand Rapids, MI  
MPA ACE 2017

**Key Points**

- **New Long-acting Insulins**
  - Insulin glargine (Toujeo<sup>®</sup>)
  - Insulin degludec (Tresiba<sup>®</sup>)
  - Insulin glargine (Basaglar<sup>®</sup>)
  - Degludec/liraglutide (Xultophy<sup>®</sup>)
  - Insulin glargine/lixisenatide (Soliqua<sup>TM</sup>)

- **New Short-acting Insulins**
  - Inhaled Insulin (Afrezza<sup>®</sup>)

<table>
<thead>
<tr>
<th>Product</th>
<th>How Supplied</th>
<th>Onset</th>
<th>Peak Glycemic Effect</th>
<th>Administration</th>
<th>Comments</th>
</tr>
</thead>
</table>
| Insulin glargine (Toujeo<sup>®</sup>)        | 300 Units/mL Solostar Pen (1.5 mL) | 6 hrs  | No peak              | Daily          | More units of insulin often necessary  
|                                              |                                     |        |                      |                | Potentially less hypoglycemia and weight gain                            |
|                                              |                                     |        |                      |                | Cost vs Basaglar                                                         |
| Insulin degludec (Tresiba<sup>®</sup>)       | 100 units/mL 200 units/mL FlexTouch (3 mL) | ~1 hr  | 9 hrs                | Daily at varied times | Flex dosing  
|                                              |                                     |        |                      |                | Potentially less hypoglycemia                                              |
|                                              |                                     |        |                      |                | Unlikely CV risk                                                         |
| Insulin glargine (Basaglar<sup>®</sup>)      | 100 units/mL KwikPen (3 mL)         | 3-4 hrs| No peak              | Daily          | Not biosimilar  
|                                              |                                     |        |                      |                | Essentially the same as Lantus<sup>®</sup>                                |
|                                              |                                     |        |                      |                | Price point may make or break this product                              |
| Degludec/liraglutide (Xultophy<sup>®</sup>)  | insulin degludec 100 units/mL and liraglutide and 3.6 mg/mL | Degludec: ~1 hr | Degludec: 9 hrs     | Daily          | Decreases post-prandial glucose levels  
|                                              |                                     |        |                      |                | Weight loss  
|                                              |                                     |        |                      |                | Single injection step-up therapy without increase in pill burden          |
|                                              |                                     |        |                      |                | REMS                                                                     |
| Insulin glargine/lixisenatide (Soliqua<sup>TM</sup>) | Insulin glargine 100 units and lixisenatide 33 mcg/mL (3 mL) | Glargine: 3-4 hr | Glargine: no peak | Daily          | Decreases post-prandial glucose levels  
|                                              |                                     |        |                      |                | Weight loss  
|                                              |                                     |        |                      |                | Single injection step-up therapy without increase in pill burden          |
|                                              |                                     |        |                      |                | REMS                                                                     |
| Inhaled Insulin (Afrezza<sup>®</sup>)        | 4, 8, 12 unit cartridges             | 12-15 min | 53 min              | With meals     | Interesting delivery  
|                                              |                                     |        |                      |                | Not commonly prescribed                                                  |
Selected References


- Riddle MC et al. New Insulin Glargine 300 Units/mL versus Glargine 100 units/mL in People with Type 2 Diabetes using Basal and Mealtime Insulin: Glucose Control and Hypoglycemia in a 6–month Randomized Controlled Trial (EDITION 1.) Diabetes Care 2014;37:2755-2762.

- Yki-Jarvinen H et al. New Insulin Glargine 300 Units/mL versus Glargine 100 units/mL in People with Type 2 Diabetes using Oral Agents and Basal Insulin: Glucose Control and Hypoglycemia in a 6–month Randomized Controlled Trial (EDITION 2). Diabetes Care 2014;37:3235-3243.

- Bolli GB et al. New Insulin Glargine 300 Units/mL compared with Glargine 100 units/mL in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3.) Diabetes, Obesity and Metabolism 2015;17:386-394.

- Home PD et al. New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4). Diabetes Care 2015;38:2217-2225.


- Lingvay I et al. Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients with Uncontrolled Type 2 Diabetes. The DUAL V Randomized Clinical Trial. JAMA 2016;315(9):898-907.


